Patterns of Intracranial Glioblastoma Recurrence After Aggressive Surgical Resection and Adjuvant Management: Retrospective Analysis of 43 Cases

Abstract

The present retrospective study evaluated the recurrence patterns after aggressive surgical removal of intracranial glioblastomas in 43 consecutive adult patients. The resection rate of the enhanced lesion on magnetic resonance imaging was 100% and 95-99% in 22 and 21 cases, respectively. All patients received postoperative fractionated radiotherapy (60 Gy in 30 fractions) with additional chemotherapy (25 cases) or vaccine therapy (18 cases). During follow-up (median 17 months), tumor recurrence was identified in 33 patients, most frequently regional within the wall of the resection cavity (20 cases). No clinical factor differed significantly between the groups of patients with regional or marginal tumor progression (N ＝ 22) and patients with distant or multiple recurrences (N ＝ 8). Progression-free survival did not differ significantly between these two groups (p ＝ 0.27). However, overall survival was significantly longer (p ＝ 0.04) in patients with regional or marginal tumor progression, and constituted 90% and 54% at 1 and 2 years after surgery, respectively, compared to 75% and 0% in patients with distant or multiple recurrences. Aggressive surgical resection and adjuvant management of intracranial glioblastoma may change its recurrence pattern. Tumor progression appears in the wall of the resection cavity or within 2 cm from its margin in approximately half of patients.

EXPANDS: expanding ploidy and allele frequency on nested subpopulations

“…Glioblastoma (GBM), a grade IV astrocytoma, is the most common CNS tumor in adults. Despite aggressive standard therapy, consisting of surgery, radiation and adjuvant chemotherapy with the DNA alkylating drug temozolomide (Stupp et al , 2009), GBM invariably recur within months following initial diagnosis (Konishi et al , 2012) and typically become resistant to the first line therapy they have been exposed (Fan et al , 2010; Lomonaco et al , 2009). An SP with stem-like properties, the cancer stem cells, is one potential culprit for recurrence and therapy resistance in GBM (Chen et al , 2012; Schonberg et al , 2013).…”

Insights into molecular therapy of glioma: current challenges and next generation blueprint

“…Recurrence often occurs as a local continuous growth within 2-3 cm of the lesion margin, at the original tumor site, through newly formed parenchymal lesions, or as unusual relapse patterns in midline tumors [47] . GBM recurrence after treatment occurs either from the bulk of the mass or within 20 mm of its boundary as detected by T1-weighted MR imaging (~97% of cases) [48] . Gadolinium-enhanced MR imaging, PET and MR spectroscopy are also used in surveillance of recurrent GBM [47] .…”

Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect

“…Furthermore, glioblastoma multiforme cells are highly invasive, and the presence of even a small number of remaining cells makes post-surgical recurrence essentially universal within this patient population. 26 The residual cells that remain in the brain are supported by the existing vasculature and due …”